KRAS G12C Inhibitor JMKX001899 clinical trials
Also written JMKX001899.
Its developmentBy Jemincare, step by step3 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses KRAS G12C Inhibitor JMKX001899 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the KRAS G12C Inhibitor JMKX001899 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JMKX001899
- 3
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses KRAS G12C Inhibitor JMKX001899 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLCNot yet recruitingPhase 3JemincareNCT07242274Written as JMKX001899
- To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy SubjectsNot yet recruitingPhase 1JemincareNCT06473948Written as JMKX001899
- Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy SubjectsNot yet recruitingPhase 1JemincareNCT06348290Written as JMKX001899